Skip to main
XAIR

XAIR Stock Forecast & Price Target

XAIR Analyst Ratings

Based on 1 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Beyond Air is a commercial-stage medical device and biopharmaceutical company with a positive outlook. Their primary source of revenue is their LungFit platform, which uses NO generated from ambient air to treat respiratory conditions. Despite near-term monetization risks, the company's strategic objective of maximizing value from their assets through partnerships, licensing, or future transactions could still bring significant value to the company. The stockholder and employee risks mentioned may impact the company's bottom line, but overall they have a solid product and technology with potential for future growth.

Bears say

Beyond Air is entering a new phase with a transition in leadership, signaling a shift towards focusing on commercial execution and generating revenues through broader market adoption of its LungFit PH technology. This change in strategy, along with the potential monetization of its NeuroNOS platform, could bring in additional funds for the company and provide shareholders with greater optionality in the future. However, its current reliance on its LungFit platform for majority of its revenue and potential risks associated with its NeuroNOS platform could impact its financial performance in the short term.

XAIR has been analyzed by 1 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Beyond Air Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Beyond Air Inc (XAIR) Forecast

Analysts have given XAIR a Strong Buy based on their latest research and market trends.

According to 1 analysts, XAIR has a Strong Buy consensus rating as of Jul 20, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Beyond Air Inc (XAIR)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.